Table 1.
DOX Concentrations per Group and Bladder Wall Layer
| Group | Mucosa | Detrusor | Serosa |
|---|---|---|---|
| iv DPPG2-TSL-DOX (low dose) + HT | 3.29 ± 0.94 | 1.63 ± 0.34 | 1.28 ± 0.15 |
| iv DPPG2-TSL-DOX (low dose) + ext. HT | 2.91 ± 0.73 | 1.29 ± 0.25 | 1.21 ± 0.12 |
| iv DPPG2-TSL-DOX (low dose) - HT | <0.20* | <0.20* | 0.24 ± 0.04 |
| iv free DOX (low dose) + HT | 0.61 ± 0.15 | 0.22 ± 0.02 | 0.37 ± 0.03 |
| iv DPPG2-TSL-DOX (full dose) + HT | 25.10 ± 2.74 | 13.11 ± 1.86 | 10.33 ± 1.28 |
| intraves DOX (full dose) - HT | 9.62 ± 3.77 | 0.64 ± 0.23 | 2.33 ± 2.07 |
| intraves DOX (full dose) + HT | 4.66 ± 1.11 | 0.30 ± 0.03 | 0.36 ± 0.11 |
Notes: Concentrations are ± standard error of mean in ng/mg; *Represents below limit of quantification.
Abbreviations: DOX, doxorubicin; DPPG2, 1.2-dipalmitoyl-sn-glycero-3-phosphodiglycerol; HT, hyperthermia; intraves intravesical; iv, intravenous; TSL, thermosensitive liposomes.